TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Torrent Pharmaceuticals Ltd.
TORNTPHARMMid CapNSEBSE
Healthcare · Healthcare
₹5,020.50up 21.50up 0.43 percentas of 28 Aug 2026
Book value ₹246.34Div yield 0.76%
Key metrics
- Market Cap
- 1,87,839.85 ₹ cr
- P/E
- 79.00 x
- P/B
- 20.38 x
- ROE
- 4.69%
- ROCE
- 4.87%
- Debt to Equity
- 0.55 x
- Net Margin
- 11.13%
- Dividend Yield
- 0.76%
- Revenue Growth (YoY)
- 54.85%
Observations
Mechanical observations generated from stored data, not analysis or opinion. Each one names the threshold that produced it — the ROCE check below uses 20%, a fixed default rather than a value tailored to this company.
- ROCE above 20% in 2 of the last 3 financial years (2023-2024, 2024-2025, 2025-2026).
- Revenue grew year-on-year in each of the last 3 years.
- Net margin declined year-on-year in 1 of the last 3 years.
- Promoter holding 60.8% (pledge data not available).
- Debt-to-equity 0.55 — above the Healthcare median of 0.31.
TORNTPHARM
₹5,020.50up 0.43 percent
EOD Synced: 28 Aug 2026 18:30 ISTOverview & Live Price Chart
Executive Investment Verdict & Quality Synthesis
Autonomous V2Multi-dimensional quantitative synthesis across capital efficiency, forensic accounting, intrinsic valuation, and ownership governance.
Factual Quantitative Consensus
1. Capital Efficiency & MoatCapital Intensive
9.32%ROCE
ROE: 25.79%·P/B: 20.38x
2. Forensic Health & SolvencyPiotroski 4/9 · Adequate Health
4/9Piotroski Score
Altman: 1.5 (Grey Zone)
3. Valuation & DCF Spread-76.3% Valuation Premium
₹1,192DCF Fair Value
CMP: ₹5,020.5
4. Ownership & GovernanceClean Promoter Holding
60.78%Promoter Stake
Pledged: 0.0%·Inst: 26.24%
Institutional Factor Scores
QVGM Factor Grade Matrix
Institutional Multi-Factor Profile (QVGM)
Composite 0–100 percentile ranks normalized across all 500 universe constituents
Rank #43 of 46 in HealthcareQVGM 42/100
Quality (Q)25
ROE, ROCE, Margins & Cash Conversion
Value (V)18
P/E, P/B, EV/EBITDA vs Sector Benchmarks
Growth (G)56
3Y Sales & EPS Compounded Growth
Momentum (M)78
Relative Strength & Trend Position
TheScreener Radar™ 5-Pillar Quantitative Scorecard
Holistic quantitative radar evaluating fundamental quality, valuation multiples, balance sheet health, growth, and price momentum
Sector Rank:Rank #43 of 46 in Healthcare
Valuation
Weak18/100
P/E Ratio:79.00x
P/B Ratio:20.38x
Dividend Yield:0.76%
P/E, P/B, EV/EBITDA & Dividend Yield relative to 5Y medians and sector
Growth
Moderate56/100
3Y Sales CAGR:—
3Y PAT CAGR:—
Quarterly YoY:+12.4%
3-Year Compounded Sales & Net Profit Growth trajectory
Profitability
Weak25/100
ROE:25.8%
ROCE:9.3%
OPM %:—
Return on Equity (ROE), ROCE & Operating Margin efficiency
Solvency & Health
Moderate44/100
Piotroski F-Score:4/9
Altman Z-Score:1.54
Debt / Equity:0.00
Balance Sheet strength, Altman Z-Score & Piotroski F-Score checklist
Momentum
Strong78/100
1Y Return:—
RSI (14):54.2
From 52W High:—
1-Year Relative Strength vs NIFTY 500, RSI-14 & 52W High distance
Quantitative Drivers & Growth Analysis
52-week corridor, deep valuation multiples, compounded CAGR trajectory, and institutional flow shifts
52-Week Low₹3,514.70
From 52W High-2.00%
52-Week High₹5,122.80
Valuation MultiplesCash Flow & Yield
PEG Ratio3.66
Earnings Yield1.26%
Price / FCF—
FCF Yield-0.60%
Payout Ratio60.06%
Net-Net Ratio-3.21
Solvency & SafetyPiotroski & Altman
Piotroski F-Score4/9
Altman Z-Score1.54
Graham Number₹592.19
1Y Flow & Margin ShiftsTrailing 12M
FII Stake:▲ +2.53%
DII Stake:▲ +3.33%
OPM Margin:▼ 1.23%
Net Margin:▼ 1.12%
Compounded Annual Growth Rate (CAGR Matrix)
Historical Fundamental Trajectory| Metric | QoQ Shift | YoY Shift | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Revenue Growth | ▲ +17.26% | ▲ +54.85% | 21.39% | 13.27% | 11.80% |
| Net Profit Growth | ▲ +45.36% | ▲ +3.28% | 13.19% | 20.22% | 11.56% |
| EPS Growth | ▲ +19.07% | ▼ 5.50% | 15.00% | 21.57% | 12.10% |
Intrinsic Valuation Models & DCF Sensitivity
Institutional DCF & Intrinsic Valuation Studio — TORNTPHARM
2-Stage Discounted Cash Flow, Reverse DCF Implied Growth, and Benjamin Graham & Peter Lynch valuation benchmarks.
DCF Intrinsic Fair Value
₹1,300.0
Verdict:Overvalued (-74.1%)
Benjamin Graham Number
₹604.4
-88% vs CMPPeter Lynch Fair Value
₹349.9
-93% vs CMPReverse DCF Implied Growth
55.3% CAGR
Aggressive Expectations (Priced for Perfection)Valuation Spectrum PositioningCMP: ₹5,020.5
₹0 (Distress)CMP: ₹5,021DCF: ₹1,300Graham: ₹604
Scenario Calibration & Sensitivity Levers
Tune Discount Rate (WACC), 5-Year Growth, and Terminal Value to model bear, base, and bull cases.
Discount Rate (WACC)11.5%
Cost of Capital Hurdle
5-Year FCF Growth CAGR17.2%
Assumed stage-1 cash flow expansionTerminal Growth Rate4.5%
Long-term perpetual GDP growth rate5-Year Projected Cash Flow Schedule (₹ Cr)
| Projection Period | Growth Rate | Projected FCF | Discount Factor | Present Value |
|---|---|---|---|---|
| Year 1 | 17.2% | ₹2,749 | 0.8969 | ₹2,465 |
| Year 2 | 17.2% | ₹3,221 | 0.8044 | ₹2,591 |
| Year 3 | 17.2% | ₹3,776 | 0.7214 | ₹2,724 |
| Year 4 | 17.2% | ₹4,425 | 0.6470 | ₹2,863 |
| Year 5 | 17.2% | ₹5,186 | 0.5803 | ₹3,009 |
2D Sensitivity Matrix (WACC vs Terminal Growth Rate)
Click any cell to apply WACC & terminal growth scenario. Values in ₹ / share.| WACC \ g(Terminal) | 3.0% | 4.0% | 4.5% | 5.0% | 6.0% |
|---|---|---|---|---|---|
| 10.0% | ₹1390 -72% | ₹1639 -67% | ₹1798 -64% | ₹1988 -60% | ₹2512 -50% |
| 11.0% | ₹1149 -77% | ₹1329 -74% | ₹1440 -71% | ₹1570 -69% | ₹1906 -62% |
| 11.5% | ₹1050 -79% | ₹1206 -76% | ₹1300 -74% | ₹1409 -72% | ₹1686 -66% |
| 12.0% | ₹962 -81% | ₹1097 -78% | ₹1179 -77% | ₹1271 -75% | ₹1503 -70% |
| 13.0% | ₹813 -84% | ₹917 -82% | ₹979 -81% | ₹1048 -79% | ₹1216 -76% |
Discounted cash flow (DCF) and valuation models are quantitative projections based on user-supplied assumptions — not a forecast, not a guarantee of future performance, and not SEBI-registered investment advice. Actual financial performance and stock price movements may differ materially.
New to intrinsic valuation models? Learn how Discounted Cash Flow and Terminal Growth rates work.Read DCF Academy Guide →
Valuation history
P/E79.00current
ReportedComputed, approximate
P/B20.38current
ReportedComputed, approximate
The dashed line is computed from historical close price divided by the most recently reported annual EPS or book value — not IndianAPI's own figure, which only ever gives a single current reading with no history behind it. Real results are typically disclosed several weeks after the fiscal year ends, so a computed point right around a year transition can lag what the market actually knew that day. The solid line is the real reported figure.
EV/EBITDA is not shown — there is no verified source for it in our data feed, and estimating it would misrepresent an estimate as a reported figure.
| Date | P/E | P/B |
|---|---|---|
| 31 Aug 2026 | 79.00 | 20.38 |
Analyst Consensus, Price Targets & Forecasts
Analyst Consensus & Recommendations
Aggregated institutional equity research ratings · 31 Aug 2026
Buy(2.07 / 5)
Strong Buy:9
Buy:12
Hold:7
Sell:2
Strong Sell:0
Coverage: 30 contributing analystsScale: 1 (Strong Buy) – 5 (Strong Sell)
Ratings shown are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Risk Profile & Volatility
Statistical return volatility classification · 31 Aug 2026
Moderate risk
Low RiskModerate RiskHigh Risk
Annualised Standard Deviation:23.90%
Analyst Price Targets
12-month forward price consensus · 31 Aug 2026
Upside: +5.25%
Mean Target₹5,284.00vs CMP ₹5,020.50
High Target₹6,194.00+23.4% max upside
Low Target₹3,770.00-24.9% downside
Median Target₹5,399.0030 estimates
Low: ₹3,770.00Mean: ₹5,284.00High: ₹6,194.00
Mean Target Current Price (₹5,020.50)
Price targets are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Forward Financial Forecasts & Consensus Estimates
Institutional broker consensus estimates and forward earnings trajectory
FY2024EConsensus
Mean Estimate
₹13.27
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹11.39
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹11.18
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹10.50
Low:—
High:—
FY2025E4 Analysts
Mean Estimate
₹13.37
Low:—
High:—
FY2025EConsensus
Mean Estimate
₹13.51
Low:—
High:—
FY2025E4 Analysts
Mean Estimate
₹14.88
Low:—
High:—
FY2025E3 Analysts
Mean Estimate
₹15.42
Low:—
High:—
FY2026E6 Analysts
Mean Estimate
₹13.46
Low:—
High:—
FY2026E2 Analysts
Mean Estimate
₹16.19
Low:—
High:—
FY2026E3 Analysts
Mean Estimate
₹19.07
Low:—
High:—
FY2026E1 Analysts
Mean Estimate
₹17.83
Low:—
High:—
FY2027E5 Analysts
Mean Estimate
₹15.42
Low:—
High:—
FY2027E2 Analysts
Mean Estimate
₹15.38
Low:₹12.00
High:₹18.00
FY2027E2 Analysts
Mean Estimate
₹20.60
Low:₹19.00
High:₹21.00
FY2027E2 Analysts
Mean Estimate
₹16.38
Low:₹15.00
High:₹17.00
FY2028E1 Analysts
Mean Estimate
₹19.05
Low:₹19.00
High:₹19.00
| Period / Fiscal Year | Consensus Mean | Bull Case (High) | Bear Case (Low) | Brokers |
|---|---|---|---|---|
| FY2024 Forecast | ₹13.27 | — | — | — |
| FY2024 Forecast | ₹11.39 | — | — | — |
| FY2024 Forecast | ₹11.18 | — | — | — |
| FY2024 Forecast | ₹10.50 | — | — | — |
| FY2025 Forecast | ₹13.37 | — | — | 4 |
| FY2025 Forecast | ₹13.51 | — | — | — |
| FY2025 Forecast | ₹14.88 | — | — | 4 |
| FY2025 Forecast | ₹15.42 | — | — | 3 |
| FY2026 Forecast | ₹13.46 | — | — | 6 |
| FY2026 Forecast | ₹16.19 | — | — | 2 |
| FY2026 Forecast | ₹19.07 | — | — | 3 |
| FY2026 Forecast | ₹17.83 | — | — | 1 |
| FY2027 Forecast | ₹15.42 | — | — | 5 |
| FY2027 Forecast | ₹15.38 | ₹18.00 | ₹12.00 | 2 |
| FY2027 Forecast | ₹20.60 | ₹21.00 | ₹19.00 | 2 |
| FY2027 Forecast | ₹16.38 | ₹17.00 | ₹15.00 | 2 |
| FY2028 Forecast | ₹19.05 | ₹19.00 | ₹19.00 | 1 |
Third-party broker forecasts compiled from institutional research houses, not IndiScreener's proprietary estimates. Provided strictly for analytical benchmarking and does not constitute investment advice.
Forensic Accounting Audit & Solvency Risk
Accounting Health & Governance Quality Radar
Algorithmic accounting analysis across balance sheet solvency, cash conversion efficiency, and ownership stability.
Clean Governance & Solvency
Financial Strengths & Catalysts
5 Factors- •Company has delivered a high Return on Equity (ROE) of 25.8%.
- •Net profit has grown at an impressive 20.2% CAGR over 3 years.
- •Strong cash generation: Operating Cash Flow is 139.7% of reported Net Profit.
- •High promoter holding of 60.8% with zero encumbrance / pledge.
- •High institutional backing: FIIs & DIIs hold a combined 26.2%.
Risk Factors & Watchouts
1 Watchout- •Stock is trading at an elevated valuation multiple of 79.0x P/E.
Forensic Accounting & Health Audit
Piotroski F-Score, Altman Z-Score Distress Model & Beneish Earnings Manipulation Checks
Piotroski F-Score4 / 9
● Moderate (Neutral)
Altman Z-Score1.54
● Grey Zone
Moderate risk; company exhibits average leverage and liquidity.
Beneish M-Score-2.30
● Low Risk (Clean Accounting)
Cash flows closely match reported earnings with conservative accruals.
Learn how Piotroski F-Score (9 criteria) and Altman Z-Score detect earnings manipulation and bankruptcy risk.Read Forensic Guide →
10-Year Financial Statements & DuPont ROE
Financial Statements
consolidated · amounts in ₹ Crores
Accounting Flow:
Wall Street Cash Flow & Free Cash Flow (FCF) Cascade
FY26 (2025-2026)3-Stage institutional flow from reported earnings to owner Free Cash Flow and capital allocation
FCF Conversion Rate (FCF / PAT)
108.4%Elite Cash Quality (>100%)
Measures how much reported accounting profit turns into real liquid cash.
Free Cash Flow Margin
16.8%of Gross Revenue
Liquid cash retained per ₹100 of top-line revenue generated.
CapEx Reinvestment Rate
22.4%of Operating Cash
Portion of operating cash reinvested in future capacity and maintenance.
Reported Net Profit (PAT)₹2,163 CrInflow
2,163
+ D&A Non-Cash Charge₹1,119 CrAdd-back
1,119
Working Capital Adjustment-₹259 Cr- Tied Up
259
= Operating Cash Flow (CFO)₹3,023 CrOperating Cash
3,023
- Capital Expenditures (CapEx)-₹677 CrReinvestment
677
= Free Cash Flow (FCF)₹2,345 CrFree Cash Flow
2,345
- Dividends & Debt Repayment-₹476 CrCapital Return
476
= Net Change in Cash₹1,869 CrNet Balance
1,869
Multi-Year Historical FCF vs Reported PAT Trajectory:
Free Cash Flow (FCF) Reported Net Profit (PAT)
| Metric | 2018-201931 Mar 2019 | 2019-202031 Mar 2020 | 2020-202131 Mar 2021 | 2021-202231 Mar 2022 | 2022-202331 Mar 2023 | 2023-202431 Mar 2024 | 2024-202531 Mar 2025 | 2025-202631 Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7,672.80 | ₹7,939.31 | ₹8,004.83 | ₹8,508.04 | ₹9,620.15 | ₹10,727.84 | ₹11,516.09 | ₹13,979.73 |
| Operating profit | ₹1,008.36 | ₹1,515.98 | ₹1,827.89 | ₹1,284.41 | ₹2,135.46 | ₹2,559.38 | ₹2,901.85 | ₹3,350.84 |
| OPM | 13.14% | 19.09% | 22.83% | 15.10% | 22.20% | 23.86% | 25.20% | 23.97% |
| Net profit | ₹436.28 | ₹1,024.72 | ₹1,251.88 | ₹777.18 | ₹1,245.23 | ₹1,656.38 | ₹1,911.25 | ₹2,163.37 |
| EPS | 21.16 | 28.79 | 37.00 | 32.05 | 36.45 | 47.37 | 56.95 | 65.49 |
| Net margin | 5.69% | 12.91% | 15.64% | 9.13% | 12.94% | 15.44% | 16.60% | 15.48% |
| ROE | 9.23% | 21.25% | 21.45% | 13.06% | 20.09% | 24.16% | 25.18% | 25.79% |
| ROCE | 11.26% | 17.72% | 19.91% | 14.79% | 22.33% | 26.56% | 28.25% | 9.32% |
| Debt / equity | 1.28 | 1.21 | 0.84 | 0.68 | 0.87 | 0.59 | 0.42 | 1.79 |
Compounded growth (CAGR)
| Metric | 1Y | 3Y | 5Y |
|---|---|---|---|
| Revenue | 21.39% | 13.27% | 11.80% |
| Net profit | 13.19% | 20.22% | 11.56% |
| EPS | 15.00% | 21.57% | 12.10% |
Each column only appears when 8 real reported years actually support it — never extrapolated from fewer.
Balance sheet
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Total assets | ₹14,120.92 | ₹14,009.74 | ₹14,074.65 | ₹13,099.84 | ₹15,011.85 | ₹15,060.58 | ₹14,989.74 | ₹44,311.96 |
| Total liabilities | ₹9,396.57 | ₹9,186.52 | ₹8,237.48 | ₹7,146.89 | ₹8,813.78 | ₹8,204.43 | ₹7,399.05 | ₹35,923.53 |
| Total equity | ₹4,724.35 | ₹4,823.22 | ₹5,837.17 | ₹5,952.95 | ₹6,198.07 | ₹6,856.15 | ₹7,590.69 | ₹8,388.43 |
| Total debt | ₹6,038.10 | ₹5,840.03 | ₹4,874.13 | ₹4,069.65 | ₹5,368.56 | ₹4,021.94 | ₹3,202.32 | ₹15,025.50 |
| Cash | ₹550.21 | ₹406.06 | ₹557.63 | ₹375.59 | ₹470.55 | ₹435.85 | ₹341.96 | ₹442.01 |
| Current assets | ₹5,037.53 | ₹4,980.92 | ₹5,523.22 | ₹5,294.65 | ₹5,329.18 | ₹5,611.48 | ₹5,622.57 | ₹9,391.89 |
| Current liabilities | ₹5,165.32 | ₹5,454.16 | ₹4,891.62 | ₹4,415.09 | ₹5,447.30 | ₹5,425.25 | ₹4,717.19 | ₹8,343.33 |
| Inventory | ₹2,019.07 | ₹2,212.31 | ₹2,734.17 | ₹2,518.92 | ₹2,280.88 | ₹2,323.96 | ₹2,600.35 | ₹3,219.65 |
| Receivables | ₹1,444.93 | ₹1,649.66 | ₹1,523.51 | ₹1,632.53 | ₹1,945.75 | ₹1,844.59 | ₹1,866.67 | ₹3,055.85 |
| Payables | ₹2,096.74 | ₹2,048.81 | ₹2,066.81 | ₹1,674.44 | ₹1,678.80 | ₹2,089.32 | ₹1,820.02 | ₹2,357.61 |
| Net PP&E | ₹3,279.99 | ₹3,529.92 | ₹3,628.75 | ₹3,246.93 | ₹3,459.84 | ₹3,577.77 | ₹3,822.91 | ₹5,366.02 |
| Retained earnings | ₹4,622.03 | ₹4,898.70 | ₹5,812.14 | ₹5,922.35 | ₹6,228.59 | ₹6,867.80 | ₹7,671.95 | ₹8,649.46 |
Cash flow
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | ₹1,798.08 | ₹1,392.91 | ₹2,005.35 | ₹1,802.99 | ₹2,426.96 | ₹3,266.08 | ₹2,585.11 | ₹3,022.71 |
| Capital expenditure | ₹-662.83 | ₹-406.78 | ₹-335.15 | ₹-202.57 | ₹-573.94 | ₹-432.78 | ₹-611.87 | ₹-677.39 |
| Free cash flow | ₹1,135.25 | ₹986.13 | ₹1,670.20 | ₹1,600.42 | ₹1,853.02 | ₹2,833.30 | ₹1,973.24 | ₹2,345.32 |
| OCF / net profit | 4.12 | 1.36 | 1.60 | 2.32 | 1.95 | 1.97 | 1.35 | 1.40 |
| FCF / Capex intensity | 8.64 | 5.12 | 4.19 | 2.38 | 5.97 | 4.03 | 5.31 | 4.85 |
Income statement detail
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | ₹5,351.13 | ₹5,686.79 | ₹5,769.53 | ₹5,970.57 | ₹6,792.46 | ₹7,940.11 | ₹8,631.60 | ₹10,454.62 |
| Cost of revenue | ₹2,321.67 | ₹2,252.52 | ₹2,235.30 | ₹2,537.47 | ₹2,827.69 | ₹2,787.73 | ₹2,884.49 | ₹3,525.11 |
| EBITDA | ₹1,622.75 | ₹2,167.49 | ₹2,485.20 | ₹1,946.34 | ₹2,837.49 | ₹3,354.68 | ₹3,696.78 | ₹4,469.43 |
| Income before tax | ₹561.66 | ₹1,186.57 | ₹1,526.26 | ₹1,225.91 | ₹1,847.16 | ₹2,352.11 | ₹2,672.81 | ₹2,872.19 |
| Interest expense | ₹446.51 | ₹328.46 | ₹303.54 | ₹66.10 | ₹316.03 | ₹327.07 | ₹231.07 | ₹498.75 |
| Tax expense | ₹125.35 | ₹214.67 | ₹274.38 | ₹448.73 | ₹601.93 | ₹695.73 | ₹761.56 | ₹734.01 |
| D&A | ₹614.39 | ₹651.51 | ₹657.31 | ₹661.93 | ₹702.03 | ₹795.30 | ₹794.93 | ₹1,118.59 |
| EBITDA margin | 21.15% | 27.30% | 31.05% | 22.88% | 29.50% | 31.27% | 32.10% | 31.97% |
Financial ratios
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.98 | 0.91 | 1.13 | 1.20 | 0.98 | 1.03 | 1.19 | 1.13 |
| Quick ratio | 0.58 | 0.51 | 0.57 | 0.63 | 0.56 | 0.61 | 0.64 | 0.74 |
| Interest coverage | 2.26 | 4.62 | 6.02 | 19.43 | 6.76 | 7.83 | 12.56 | 6.72 |
| Inventory days | 317.43 | 358.48 | 446.46 | 362.33 | 294.42 | 304.28 | 329.05 | 333.37 |
| Receivable days | 68.74 | 75.84 | 69.47 | 70.04 | 73.82 | 62.76 | 59.16 | 79.79 |
| Payable days | 329.64 | 331.99 | 337.49 | 240.86 | 216.70 | 273.56 | 230.30 | 244.11 |
| Cash conversion cycle | 56.53 | 102.33 | 178.44 | 191.51 | 151.54 | 93.48 | 157.91 | 169.04 |
| Working capital days | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 |
| Fixed asset turnover | 2.34 | 2.25 | 2.21 | 2.62 | 2.78 | 3.00 | 3.01 | 2.61 |
| ROA | 3.09% | 7.31% | 8.89% | 5.93% | 8.30% | 11.00% | 12.75% | 4.88% |
| ROIC | 7.67% | 12.11% | 14.77% | 8.44% | 12.97% | 17.26% | 19.85% | 10.86% |
| Gross margin | 69.74% | 71.63% | 72.08% | 70.18% | 70.61% | 74.01% | 74.95% | 74.78% |
DuPont 3-Stage ROE Factor Decomposition
Deconstructing Return on Equity into Profitability, Asset Efficiency, and Financial Leverage
Leverage Driven (Elevated Debt Contribution)FY2025-2026
Net marginProfitability
15.48%
Net Profit generated per ₹100 of revenue (Profitability)
×
Asset turnoverEfficiency
0.32
Revenue generated per ₹1 of total assets (Capital Efficiency)
×
Equity multiplierLeverage
5.28
Total assets supported per ₹1 of shareholder equity (Leverage)
=
Implied DuPont ROEFinal Output
25.79%
Reported: 25.79%
Explore the 3-Stage DuPont Formula: Net Margin × Asset Turnover × Leverage Multiplier.Read DuPont Guide →
Corporate Actions, Dividends & Capital Changes
Chronological Corporate Actions Registry
Historical stock splits, bonus shares, rights issues, and corporate schemes
| Year | Execution Date | Action Type | Ratio / Term |
|---|---|---|---|
| 2026 | 29 May 2026 | dividend | 180% |
| 19 Feb 2026 | dividend | 580% | |
| 2025 | 01 Feb 2025 | dividend | 520% |
| 2024 | 21 Jun 2024 | dividend | 120% |
| 12 Feb 2024 | dividend | 440% | |
| 2023 | 23 Jun 2023 | dividend | 160% |
| 03 Feb 2023 | dividend | 280% | |
| 2022 | 11 Jul 2022 | bonus | 1:1 |
| 06 Jun 2022 | dividend | 160% | |
| 06 Jun 2022 | dividend | 300% | |
| 03 Feb 2022 | dividend | 500% | |
| 2021 | 18 Jun 2021 | dividend | 300% |
| 16 Feb 2021 | dividend | 400% | |
| 2020 | 19 Mar 2020 | dividend | 300% |
| 19 Mar 2020 | dividend | 340% | |
| 2019 | 14 Jun 2019 | dividend | 80% |
| 07 Feb 2019 | dividend | 260% | |
| 2018 | 20 Jun 2018 | dividend | 100% |
| 19 Feb 2018 | dividend | 180% | |
| 2017 | 21 Jun 2017 | dividend | 80% |
| 13 Feb 2017 | dividend | 200% | |
| 2016 | 17 Mar 2016 | dividend | 300% |
| 12 Feb 2016 | dividend | 400% | |
| 2015 | 17 Jun 2015 | dividend | 125% |
| 03 Feb 2015 | dividend | 100% | |
| 2014 | 18 Jun 2014 | dividend | 100% |
| 27 Jan 2014 | dividend | 100% | |
| 2013 | 24 Jul 2013 | bonus | 1:1 |
| 12 Jun 2013 | dividend | 200% | |
| 12 Jun 2013 | dividend | 140% | |
| 04 Feb 2013 | dividend | 120% | |
| 2012 | 13 Jun 2012 | dividend | 50% |
| 30 Jan 2012 | dividend | 120% | |
| 2011 | 08 Jun 2011 | dividend | 40% |
| 08 Jun 2011 | dividend | 120% | |
| 2010 | 08 Jun 2010 | dividend | 120% |
| 2009 | 10 Jun 2009 | dividend | 80% |
| 2008 | 23 Jun 2008 | dividend | 70% |
| 2007 | 26 Mar 2007 | dividend | 60% |
| 2006 | 19 Jun 2006 | dividend | 50% |
| 27 Feb 2006 | split | 5:10 |
Dividend Intelligence & Capital Return History
Historical cash payout track record across 13 dividend distributions
Latest Year DPS:₹38.00
Yield on CMP:0.76%
3Y Dividend CAGR:+20.0%
Annual Dividend Payout Progression (Per Share)Total Cumulative DPS: ₹203.00
₹38.0
2026
₹32.0
2025
₹28.0
2024
₹22.0
2023
₹48.0
2022
₹35.0
2021
| Ex-Date | Amount (Per Share) | Dividend Type |
|---|---|---|
| 29 May 2026 | ₹9.00 | Final |
| 18 Feb 2026 | ₹29.00 | Interim |
| 20 Jun 2025 | ₹6.00 | Final |
| 31 Jan 2025 | ₹26.00 | Interim |
| 21 Jun 2024 | ₹6.00 | Final |
| 12 Feb 2024 | ₹22.00 | Interim |
| 23 Jun 2023 | ₹8.00 | Final |
| 03 Feb 2023 | ₹14.00 | Interim |
| 03 Jun 2022 | ₹8.00 | Final |
| 03 Jun 2022 | ₹15.00 | Special |
| 02 Feb 2022 | ₹25.00 | Interim |
| 17 Jun 2021 | ₹15.00 | Final |
| 15 Feb 2021 | ₹20.00 | Interim |
Industry Peer Group & Valuation Spread
Compare valuation multiples and market cap relative to sector competitors
HealthcareCompare Peers in Studio
Market Cap1,87,839.85 ₹ cr
Beats 98% of 65 industry peers · median 21,553.63 ₹ cr
P/E79.00 x
Beats 82% of 60 industry peers · median 48.58 x
P/B20.38 x
Beats 95% of 62 industry peers · median 6.13 x
ROE4.69%
Beats 11% of 65 industry peers · median 14.40%
ROCE4.87%
Beats 8% of 65 industry peers · median 16.66%
Debt to Equity0.55 x
Beats 88% of 65 industry peers · median 0.31 x
Net Margin11.13%
Beats 22% of 65 industry peers · median 13.19%
Dividend Yield0.76%
Beats 72% of 53 industry peers · median 0.42%
Revenue Growth (YoY)54.85%
Beats 97% of 64 industry peers · median 19.05%
| Company | Market Cap ▼ | P/E | P/B |
|---|---|---|---|
Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹4.61 L | 41.52 | 5.51 |
Apollo Hospitals Enterprise Ltd.APOLLOHOSP | ₹1.27 L | 65.49 | 13.41 |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.16 L | 23.78 | 4.42 |
Cipla Ltd.CIPLA | ₹1.14 L | 29.66 | 3.34 |
Laurus Labs Ltd.LAURUSLABS | ₹1.05 L | 117.32 | 19.65 |
Peers are chosen strictly by industry classification. A classification doesn't always describe what a company actually competes in, but gives an objective starting point across the universe.
Regulatory Filings & Market Intelligence
Corporate Filings & Document Vault
SEBI LODR VerifiedAudited Annual Reports, Investor Decks, Earnings Concall Transcripts, and Board Resolutions for Torrent Pharmaceuticals Ltd. (TORNTPHARM)
Indexed Documents6 Filings
Latest Disclosure25 Jul 2026
Corporate Action25 Jul 2026
Torrent Pharmaceuticals Ltd: Recommendation of Final Dividend for the Financial Year 2025-26
Board Outcome09 Jul 2026
Torrent Pharmaceuticals Ltd: Outcome of Board Meeting for Approval of Audited Financial Results
Investor Deck03 Jul 2026
Torrent Pharmaceuticals Ltd: Investor Presentation on Q4 Financial Results and Growth Outlook
Secretarial Filing01 Jun 2026
Torrent Pharmaceuticals Ltd: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015
Press Release29 Mar 2026
Torrent Pharmaceuticals Ltd: Press Release: Business Updates and New Strategic Initiatives
News
- IndianAPIBandhan Small Cap Fund July portfolio: 15 stocks added, 9 exited; HDFC Bank, AWL Agri see higher holdings
Bandhan Small Cap Fund made significant portfolio changes in July, adding 15 new stocks and exiting nine. HDFC Bank, AWL Agri Business and Sterlite Technologies were among the key stocks where the fund raised its holdings.
- IndianAPIFrom Gift Nifty to US Fed meeting outcome: 8 key things that changed for Indian stock market overnight
Gift Nifty was trading around the 24,330 level, a discount of nearly 19 points from the Nifty futures’ previous close, indicating a gap-down start for the Indian stock market indices.
- IndianAPIFrom Gift Nifty to US Fed meeting outcome: 8 key things that changed for Indian stock market overnight
Gift Nifty was trading around the 24,330 level, a discount of nearly 19 points from the Nifty futures’ previous close, indicating a gap-down start for the Indian stock market indices.
- IndianAPIIndia tightens watch on semaglutide supply after Interpol flags counterfeit batch
State drug regulators have been told to monitor distribution networks and crack down on suspect semaglutide batches after an Interpol alert linked to a counterfeit product detected in Austria.
- IndianAPIIndia tightens watch on semaglutide supply after Interpol flags counterfeit batch
State drug regulators have been told to monitor distribution networks and crack down on suspect semaglutide batches after an Interpol alert linked to a counterfeit product detected in Austria.
- IndianAPICipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
- IndianAPICipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
- IndianAPIStock market today: Gift Nifty hints flat start; eight day trading stocks to buy on Monday, 6 July
The Indian stock market is expected to open muted on Monday amid mixed global cues. While crude oil prices remain under pressure, the Sensex and Nifty 50 both gained last Friday, marking a continued upward trend in domestic equity benchmarks.
- IndianAPIStock market today: Gift Nifty hints flat start; eight day trading stocks to buy on Monday, 6 July
The Indian stock market is expected to open muted on Monday amid mixed global cues. While crude oil prices remain under pressure, the Sensex and Nifty 50 both gained last Friday, marking a continued upward trend in domestic equity benchmarks.
- IndianAPIStock market today: Sensex falls 400 points, Nifty 50 ends below 23,950; Reliance, Kotak Mahindra Bank among top drags
The Sensex ended the day 372 points, or 0.48%, lower at 76,728.37, while the Nifty 50 settled at 23,946.25, down 110 points, or 0.46%. The Nifty Midcap 100 index dropped 0.37%, while the Smallcap 100 index declined 0.62%.
- IndianAPIStock market today: Sensex falls 400 points, Nifty 50 ends below 23,950; Reliance, Kotak Mahindra Bank among top drags
The Sensex ended the day 372 points, or 0.48%, lower at 76,728.37, while the Nifty 50 settled at 23,946.25, down 110 points, or 0.46%. The Nifty Midcap 100 index dropped 0.37%, while the Smallcap 100 index declined 0.62%.
- IndianAPIShares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 12 June 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 12 June 2026 - Torrent Pharmaceuticals, Kotak Mahindra Bank and Grasim Industries shares.
- IndianAPIShares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 12 June 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 12 June 2026 - Torrent Pharmaceuticals, Kotak Mahindra Bank and Grasim Industries shares.
- IndianAPIStock market today: Gift Nifty hints gap-up start; US-Iran peace deal to global markets rally - 7 stocks to buy
Indian markets may open positively on June 12, 2026, following a strong rally in global equities amid optimism for a US-Iran peace deal. Oil prices dropped as tensions eased, while Asian markets showed resilience, marking a rebound in investor confidence.
- IndianAPIStock market today: Gift Nifty hints gap-up start; US-Iran peace deal to global markets rally - 7 stocks to buy
Indian markets may open positively on June 12, 2026, following a strong rally in global equities amid optimism for a US-Iran peace deal. Oil prices dropped as tensions eased, while Asian markets showed resilience, marking a rebound in investor confidence.
- IndianAPISun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row
The Nifty Pharma index rose 1.4% on 8 June, defying the broader market selloff, supported by heavyweight stocks like JB Chemicals and Alkem Laboratories. Despite some losses in others, analysts suggest pharma stocks are resilient during market instability due to consistent healthcare demand.
- IndianAPISun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row
The Nifty Pharma index rose 1.4% on 8 June, defying the broader market selloff, supported by heavyweight stocks like JB Chemicals and Alkem Laboratories. Despite some losses in others, analysts suggest pharma stocks are resilient during market instability due to consistent healthcare demand.
- IndianAPICompanies turn to private market deals amid IPO slowdown, says Deloitte's Berry
While companies continue to believe in India's long-term growth story, many are choosing to wait out the current turbulence before tapping public markets, creating opportunities for private equity, private credit and strategic investors.
- IndianAPICompanies turn to private market deals amid IPO slowdown, says Deloitte's Berry
While companies continue to believe in India's long-term growth story, many are choosing to wait out the current turbulence before tapping public markets, creating opportunities for private equity, private credit and strategic investors.
- IndianAPIStocks to watch today: Hindalco, TVS Motor, Eicher Motors, NTPC, among stocks in focus on 25 May 2026
Stocks to watch today: Hindalco, TVS Motor, Eicher Motors, NTPC, Lupin, Aurobindo Pharma, Torrent Pharmaceuticals, Colgate-Palmolive (India), Camlin Fine Sciences, Groww, Tata Capital, among other stocks are in focus today.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.